MA54063B1 - Nouveau sel d'un inhibiteur de bcl-2, forme cristalline apparentée, son procédé de préparation et compositions pharmaceutiques le contenant - Google Patents

Nouveau sel d'un inhibiteur de bcl-2, forme cristalline apparentée, son procédé de préparation et compositions pharmaceutiques le contenant

Info

Publication number
MA54063B1
MA54063B1 MA54063A MA54063A MA54063B1 MA 54063 B1 MA54063 B1 MA 54063B1 MA 54063 A MA54063 A MA 54063A MA 54063 A MA54063 A MA 54063A MA 54063 B1 MA54063 B1 MA 54063B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
same
bcl
inhibitor
compositions containing
Prior art date
Application number
MA54063A
Other languages
English (en)
Other versions
MA54063A (fr
Inventor
Michael Lynch
Frédéric Villard
Patrick Mouchet
Pascal Taulelle
Ludovic Masson
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of MA54063A publication Critical patent/MA54063A/fr
Publication of MA54063B1 publication Critical patent/MA54063B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

L'invention concerne un nouveau sel et des formes cristallines associées du composé (a), le sel étant le sel de sulfate d'hydrogène, caractérisé par son diagramme de diffraction de rayons x sur poudre, son procédé de préparation et des compositions pharmaceutiques le contenant.
MA54063A 2018-10-31 2019-10-30 Nouveau sel d'un inhibiteur de bcl-2, forme cristalline apparentée, son procédé de préparation et compositions pharmaceutiques le contenant MA54063B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306430 2018-10-31
PCT/EP2019/079621 WO2020089281A1 (fr) 2018-10-31 2019-10-30 Nouveau sel d'un inhibiteur de bcl-2, forme cristalline associée, son procédé de préparation et compositions pharmaceutiques le contenant

Publications (2)

Publication Number Publication Date
MA54063A MA54063A (fr) 2021-09-08
MA54063B1 true MA54063B1 (fr) 2023-06-28

Family

ID=64270773

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54063A MA54063B1 (fr) 2018-10-31 2019-10-30 Nouveau sel d'un inhibiteur de bcl-2, forme cristalline apparentée, son procédé de préparation et compositions pharmaceutiques le contenant

Country Status (37)

Country Link
US (1) US20210355108A1 (fr)
EP (1) EP3873894B1 (fr)
JP (1) JP2022506137A (fr)
KR (1) KR20210092750A (fr)
CN (1) CN112969693A (fr)
AR (1) AR116921A1 (fr)
AU (1) AU2019370926A1 (fr)
BR (1) BR112021007194A2 (fr)
CA (1) CA3117559C (fr)
CL (1) CL2021000947A1 (fr)
CO (1) CO2021005077A2 (fr)
CR (1) CR20210211A (fr)
CY (1) CY1126057T1 (fr)
DK (1) DK3873894T3 (fr)
DO (1) DOP2021000074A (fr)
EA (1) EA202191143A1 (fr)
ES (1) ES2943511T3 (fr)
FI (1) FI3873894T3 (fr)
GE (1) GEP20237494B (fr)
HR (1) HRP20230563T1 (fr)
HU (1) HUE062000T2 (fr)
IL (1) IL282565A (fr)
JO (1) JOP20210072A1 (fr)
LT (1) LT3873894T (fr)
MA (1) MA54063B1 (fr)
MX (1) MX2021004934A (fr)
NI (1) NI202100025A (fr)
PE (1) PE20211503A1 (fr)
PH (1) PH12021550790A1 (fr)
PL (1) PL3873894T3 (fr)
PT (1) PT3873894T (fr)
RS (1) RS64236B1 (fr)
SG (1) SG11202103594XA (fr)
SI (1) SI3873894T1 (fr)
TW (1) TWI791916B (fr)
WO (1) WO2020089281A1 (fr)
ZA (1) ZA202102783B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300145A (en) 2020-07-31 2023-03-01 Servier Lab A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations
WO2022090443A1 (fr) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration et posologie pour une combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1
AR125205A1 (es) 2021-03-24 2023-06-21 Servier Lab Nuevo proceso para la síntesis de derivados del ácido 5-{5-cloro-2-[(3s)-3-[(morfolin-4-il)metil]-3,4-dihidroisoquinolina-2(1h)-carbonil]fenil}-1,2-dimetil-1h-pirrol-3-carboxílico y su aplicación para la producción de compuestos farmacéuticos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
WO2006073292A1 (fr) * 2005-01-06 2006-07-13 Cj Corporation Sels d'acide inorganique de sibutramine
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
CN101962387B (zh) * 2010-09-13 2013-01-30 成都雅途生物技术有限公司 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法
CN103664753B (zh) * 2012-09-04 2017-04-26 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3283486B1 (fr) * 2015-04-15 2022-07-27 BeiGene, Ltd. Sels de maléate d'un inhibiteur de kinase b-raf, formes cristallines, procédés de préparation, et leurs utilisations

Also Published As

Publication number Publication date
HRP20230563T1 (hr) 2023-08-18
EA202191143A1 (ru) 2021-09-10
DOP2021000074A (es) 2021-07-22
PH12021550790A1 (en) 2021-10-25
WO2020089281A1 (fr) 2020-05-07
JP2022506137A (ja) 2022-01-17
TWI791916B (zh) 2023-02-11
FI3873894T3 (fi) 2023-06-07
AR116921A1 (es) 2021-06-30
EP3873894B1 (fr) 2023-03-22
NI202100025A (es) 2021-08-24
LT3873894T (lt) 2023-06-26
SI3873894T1 (sl) 2023-08-31
BR112021007194A2 (pt) 2021-07-20
MX2021004934A (es) 2021-06-08
PT3873894T (pt) 2023-04-28
RS64236B1 (sr) 2023-06-30
KR20210092750A (ko) 2021-07-26
US20210355108A1 (en) 2021-11-18
ZA202102783B (en) 2022-10-26
EP3873894A1 (fr) 2021-09-08
PL3873894T3 (pl) 2023-07-31
AU2019370926A1 (en) 2021-05-20
MA54063A (fr) 2021-09-08
CA3117559C (fr) 2023-09-26
CO2021005077A2 (es) 2021-09-20
GEP20237494B (en) 2023-04-10
DK3873894T3 (da) 2023-06-06
CR20210211A (es) 2021-05-25
PE20211503A1 (es) 2021-08-11
IL282565A (en) 2021-06-30
HUE062000T2 (hu) 2023-09-28
SG11202103594XA (en) 2021-05-28
JOP20210072A1 (ar) 2023-01-30
TW202033517A (zh) 2020-09-16
CY1126057T1 (el) 2023-11-15
CA3117559A1 (fr) 2020-05-07
ES2943511T3 (es) 2023-06-13
CL2021000947A1 (es) 2021-11-19
CN112969693A (zh) 2021-06-15

Similar Documents

Publication Publication Date Title
MA54063B1 (fr) Nouveau sel d'un inhibiteur de bcl-2, forme cristalline apparentée, son procédé de préparation et compositions pharmaceutiques le contenant
MA30464B1 (fr) Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
MA28134A1 (fr) Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent.
UA83720C2 (ru) Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
TW200639158A (en) New compounds with therapeutic effect
MA28133A1 (fr) FORME CRISTALLINE ßd DU CHLORHYDRATE DE L'IVABRADINE, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT.
JO3360B1 (ar) الشكل البلوري الجديد 3 للأغوميلاتين وعملية تحضيره والمكونات الصيدلانية التي تحتويه
UA83718C2 (ru) Кристаллическая форма iv агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
MX2007006374A (es) Derivados del 5-hidroxi-benzotiazol que tienen actividad agonista del adrenoreceptor-beta-2.
CA2415447A1 (fr) Nouvelle forme cristalline .gamma. du sel de tert-butylamine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
MA30276B1 (fr) Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
TW200640873A (en) &bgr-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
MA27815A1 (fr) Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent.
CA2415442A1 (fr) Nouvelle forme cristalline .beta. du sel de tert-butylamine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
PH12016500838A1 (en) Isoxazolines as therapeutic agents
TN2012000619A1 (fr) Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
AP2004A (en) Polymorphic salt as an anti-migraine drug.
MX2022004265A (es) Compuesto de aldehido y metodo para producir el mismo y composicion de fragancia.
MX2023004731A (es) Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma.
MY185728A (en) Crystal form and salt of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole
MA28191A1 (fr) Nouvelle forme cristalline "alpha" du sel de tert -butylamine du perindoprill, son procede de preparation et les compositions pharmaceutiques qui la contiennent.
MA28189A1 (fr) Nouvelle forme cristalline y du sel de tert-butylamine du perindoprill, son procede de preparation et les compositions pharmaceutiques qui la contiennent
MX2023004732A (es) Forma cristalina iii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma.
TNSN08418A1 (fr) Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent